

## Commentary

Global equity strength continued for a fifth consecutive month (+2.9%) as global growth indicators picked up and COVID-19 vaccine developments progressed. Whilst some cyclical sectors outperformed, led by Consumer Discretionary and Industrials, investors continued to exhibit a preference for growth over low multiple – or value – stocks.

US equities outperformed (+4.2%) as the Fed confirmed monetary policy will remain supportive post a shift to an average inflation target. The strength in US technology giants continued unabated as investors increasingly view the tech sector as a COVID-19 haven, despite lofty valuations. Negotiations on a new COVID-19 relief bill stalled in Washington. Japanese equities led (+4.4%), quickly regaining the ground lost at the end of July. Towards the end of the month, Prime minister Shinzo Abe announced his resignation due to a long-standing health problem.

Europe underperformed (+1.0%) given its lack of technology exposure. COVID-19 cases worsened with France and Spain entering a second wave and new travel restrictions were established across the continent.

Elsewhere, global bond yields rose from record low levels as risk appetite improved. Gold halted a five month winning streak. Brent Crude (+4.0%) rallied amid the threat of tropical activity in the US Gulf Coast interrupting supply.

Key contributors to performance included:

- Consumer Cyclical Developed Markets cluster notably ING which

## Net performance (%)

	Fund	Benchmark	Difference
1 month	2.4	2.9	-0.6
3 month	2.8	3.5	-0.7
Year to date	-4.4	-0.4	-4.0
1 year	1.7	6.2	-4.4
Inception p.a.	3.3	10.7	-7.4
Inception	6.2	20.4	-14.2

Past performance is not a reliable indicator of future performance. Returns are calculated net of applicable fees, costs and taxes.

## Top 10 equity longs (%)

Name	Country	Weight
Facebook	United States	3.1
Microsoft	United States	2.9
Alibaba	China/HK	2.9
Ping An Insurance	China/HK	2.9
Siemens	Germany	2.8
Électricité de France	France	2.7
Roche	Switzerland	2.7
Tencent Holdings	China/HK	2.6
Capital One Financial	United States	2.5
Merck	United States	2.5

## iNAV tickers

	Unit Price	iNAV
Bloomberg	AGX1AU Equity	AGFLIV Index
Thomson Reuters	AGX1AX	AGFLOFV-SOLA
IRESS	AGX1AXW, AGX1.CXA	AGXIIV

reported a strong result with flat earnings and provisions expected to fall in 2H20. Excess capital places ING in a good position to pay dividends in 2021, valuing the stock on a 10% yield.

- Industrials cluster including Volkswagen and Siemens as the market become more constructive around reopening. Siemens reported another strong result driven by Digital Industries (automation, including hardware and software), where profitability rose thanks to software sales. Pleasingly, orders and market share also rose.
- Online Services in Developed and Emerging Markets including Facebook and Alibaba, as Facebook continues to announce new product initiatives and Alibaba announced its intention to separately list Ant Group, which operates AliPay.


Key detractors to performance included:

- Connectivity/Compute cluster including Samsung Electronics, TSMC and MediaTek following escalation in US-China tech tensions, preventing Huawei accessing chips designed/manufactured using US equipment, after a period of outperformance. MediaTek is temporarily affected, though we expect the three players can emerge from this transition with secular trends intact
- Newcrest as the gold price tapered, and following a period of outperformance.

## Fund facts

Characteristics	
Investment manager	Antipodes
Inception date	5 November 2018
Benchmark	MSCI All Country World Net Index in AUD
Management fee	1.10% p.a.
Performance fee	15% of net return in excess of benchmark
Distribution	Annual, 30 June
Unit valuation	Sydney business day
Asset value	
Fund AUM	\$24m
Strategy AUM	\$2,462m
Asset Value (NAV)	5.1355

## Sector exposure<sup>1</sup> (%)




<sup>1</sup> Antipodes classification

**Asset allocation<sup>3</sup>**

	Equities - Long	Other - Long
Weight (% NAV)	93.4	-
Count	65	-
Avg. weight	1.4	-
Top 10 (% NAV)	27.6	-
Top 30 (% NAV)	64.6	-

<sup>3</sup> Call (put) options represented as the current option value (delta adjusted exposure)

**Currency exposure<sup>2,3</sup> (%)**



<sup>2</sup> Where possible, regions, countries and currencies classified on a look through basis.

**Regional exposure<sup>1,2,3</sup> (%)**

Region	Long
United States	34.6
Western Europe	25.3
- Eurozone	18.7
- Rest Western Europe	4.9
- United Kingdom	1.8
Developing Asia	18.3
- China/Hong Kong	17.0
- India	1.4
Developed Asia	12.8
- Korea/Taiwan	7.9
- Japan	4.9
Australia	2.3
<b>Total Equities</b>	<b>93.4</b>
Cash	6.6
<b>Totals</b>	<b>100.0</b>

**Market cap exposure<sup>3</sup> (%)**

Band	Long
Mega (>\$100b)	40.6
Large (>\$25b <\$100b)	27.8
Medium (>\$5b <\$25b)	20.2
Small (<\$5b)	4.8

### Investment Manager

- Global pragmatic value manager, long only and long-short
- Structured to reinforce alignment between investors and the investment team
- We attempt to take advantage of the market's tendency for irrational extrapolation, identify investments that offer a high margin of safety and build portfolios with a capital preservation focus

### Fund features

- **Objective** – to achieve absolute returns in excess of the benchmark over the investment cycle (typically 3-5 years)
- **Global diversification** – Access to 30+ global companies via a single trade
- **Alignment of interests** – proportion of each team member's remuneration is invested into Antipodes funds. Antipodes also has a significant investment alongside unitholders
- **Simple access** – being exchange traded, investors can buy or sell AGX1 like a regular share during the trading day

### Fund Ratings



### Further information

☎ 1300 010 311

✉ [invest@antipodespartners.com](mailto:invest@antipodespartners.com)

### Australia Head Office

Antipodes Partners Limited  
Level 35, 60 Margaret St  
Sydney NSW 2000  
Australia

### UK Office

Antipodes Partners Limited  
6th Floor, Nova North  
11 Bressenden Place  
London SW1E 5BY UK

### Disclaimer

The Zenith Investment Partners (ABN 27 103 132 672, AFS Licence 226872) ("Zenith") rating (assigned October 2019) referred to in this document is limited to "General Advice" (s766B Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual and is subject to change at any time without prior notice. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of, and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Past performance is not an indication of future performance. Zenith usually charges the product issuer, fund manager or related party to conduct Product Assessments. Full details regarding Zenith's methodology, ratings definitions and regulatory compliance are available on our Product Assessments and at <http://www.zenithpartners.com.au/RegulatoryGuidelines>

The Lonsec Ratings (assigned March 2019) presented in this document are published by Lonsec Research Pty Ltd ABN 11 151 658 561 AFSL 421445. The Ratings are limited to "General Advice" (as defined in the Corporations Act 2001 (Cth)) and based solely on consideration of the investment merits of the financial products. Past performance information is for illustrative purposes only and is not indicative of future performance. They are not a recommendation to purchase, sell or hold Antipodes products, and you should seek independent financial advice before investing in these products. The Ratings are subject to change without notice and Lonsec assumes no obligation to update the relevant documents following publication. Lonsec receives a fee from the Fund Manager for researching the products using comprehensive and objective criteria. For further information regarding Lonsec's Ratings methodology, please refer to our website at: <http://www.beyond.lonsec.com.au/research-solutions/our-ratings>.

Interests in the Antipodes Global Shares (Quoted Managed Fund) ARSN 625 560 269 ('Fund') are issued by Pinnacle Fund Services Limited, ABN 29 082 494 362, AFSL 238371. Antipodes Partners Limited ABN 29 602 042 035 AFSL 481580 ('Antipodes') is the investment manager of the Fund. The Product Disclosure Statement (PDS) for the Fund is available at [www.antipodespartners.com](http://www.antipodespartners.com).

Pinnacle Fund Services Limited is not licensed to provide financial product advice. Any potential investor should consider the current PDS in its entirety and consult their financial adviser before making an investment decision in relation to the Fund. Antipodes and Pinnacle Fund Services Limited believe the information contained in this communication is reliable, however no warranty is given as to its accuracy and persons relying on this information do so at their own risk. Any opinions or forecasts reflect the judgment and assumptions of Antipodes and its representatives on the basis of information at the date of publication and may later change without notice. The information is not intended as a securities recommendation or statement of opinion intended to influence a person or persons in making a decision in relation to investment. This communication is for general information only. It has been prepared without taking account of any person's objectives, financial situation or needs. Any persons relying on this information should obtain professional advice before doing so. Past performance is not a reliable indicator of future performance.

To the extent permitted by law, Antipodes and Pinnacle Fund Services Limited disclaim all liability to any person relying on the information in respect of any loss or damage (including consequential loss or damage) however caused, which may be suffered or arise directly or indirectly in respect of such information contained in this communication. Options exposure represents the market downside. For put options (typically used to limit potential downside) delta-adjusted exposure is used and for call options (typically used to capture potential upside) exposure is calculated using the current option value.